Rapid Microbiology Testing Market worth $6.7 billion by 2026
The report "Rapid Microbiology Testing Market by Product (Reagents, Kits, Automated Identification System, PCR, Mass Spectrometry), Method (Growth, Nucleic Acid, Viability), Applications (Clinical Diagnosis, Pharma, Environmental) - Global Forecast to 2026" is projected to reach USD 6.7 billion by 2026, at a CAGR of 9.4%.
Browse 214 market data Tables and 41 Figures spread through 276 Pages and in-depth TOC on "Rapid Microbiology Testing Market - Global Forecast to 2026"
View detailed Table of Content here - https://www.marketsandmarkets.com/Market-Reports/rapid-microbiology-testing-market-31548521.html
Increasing incidence of infectious disease and cancer, technological advancements in rapid microbiology testing, increased funding for R&D and increased focus on the early detection of infectious disease are among the other factors. Emerging economies such as China, India, and Japan are providing lucrative opportunities for the players operating in the rapid microbiology testing market.
The cardiac Instruments segment accounted for the largest share of the rapid microbiology testing market, by product segment.
Based on product, the rapid microbiology testing market is segmented into instruments, reagents and kits, and consumables. The instruments segment accounted for the largest share of the rapid microbiology testing market. Factors such as technological advancements, increasing incidence of infectious disease and cancer and increased focus on the early detection of infectious disease are contributing to the growth of this market.
Nucleic acid-based rapid microbiology testing segment to register the highest growth rate during the forecast period
The rapid microbiology testing market is segmented into growth-based, nucleic acid-based, viability-based, cellular component-based, and another rapid microbiology testing. The nucleic acid-based segment accounted for the highest growth rate. Factors such as the increased focus on early detection of infectious disease and rising incidence of infectious diseases and cancer.
The clinical disease diagnostics segment accounted for the largest share of the rapid microbiology testing market, by applications segment.
Based on applications, the rapid microbiology testing market has been segmented into clinical disease diagnosis, food and beverage testing, pharmaceutican and biological drug testing, environmental testing, cosmetics, and personal care products testing, research applications, and other applications. The clinical disease diagnostics segment accounted for the largest share of the rapid microbiology testing market. The increasing incidence of infectious disease and cancer is driving this segments growth.
North America is the largest regional market for rapid microbiology testing market
The global rapid microbiology testing market is segmented into five major regions, namely, North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. North America accounted for the largest share of the rapid microbiology testing market. The large share of this region can be attributed to the increased funding on R&D and technological advancements in the US and Canada.
The major players operating in this market are Abbott Laboratories, Inc. (US), Becton, Dickinson and Company (US), bioMérieux SA (France), Bruker Corporation (US), Charles River Laboratories International, Inc. (US), Danaher Corporation (US), Merck KGaA (Germany), NEOGEN Corporation (US), Quidel Corporation (US), Sartorius AG (Germany), Thermo Fisher Scientific, Inc. (US), Don Whitley Scientific Limited (UK), Rapid Micro Biosystems, Inc. (US), Vivione Biosciences, LLC (US), Gradientech (Sweden), rqmicro AG (Switzerland), Bactest Ltd. (US), Colifast (Norway), Serosep Ltd. (Ireland), Biosensia (Ireland), Solus Scientific Solutions Ltd. (Scotland), LubioScience GmbH (Scotland), Euroclone SpA (Italy), CorDx (US), and R-Biopharm AG (Germany).
About MarketsandMarkets™
MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.
Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.
MarketsandMarkets’s flagship competitive intelligence and market research platform, "Knowledgestore" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.
Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
[email protected]
- Triangulate with your Own Data
- Get Data as per your Format and Definition
- Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
- Any level of Personalization
- What are the Known and Unknown Adjacencies Impacting the Rapid Microbiology Testing Market
- What will your New Revenue Sources be?
- Who will be your Top Customer; what will make them switch?
- Defend your Market Share or Win Competitors
- Get a Scorecard for Target Partners
